CRSP CRISPR Therapeutics AG

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRSP

Price (delayed)

$53.99

Market cap

$5.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.74

Enterprise value

$5.71B

?
Relative Growth: Rel. Growth: 54
Relative Strength: Rel. Strength: 38
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 35

Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of ...

Highlights
The EPS is up by 24% since the previous quarter and by 12% year-on-year
The company's net income rose by 21% QoQ and by 3.6% YoY
The equity has decreased by 3.7% QoQ but it has increased by 2.1% YoY
The company's gross profit has shrunk by 65% YoY
The revenue has dropped by 65% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.crisprtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRSP

CRSP stock price

How has the CRISPR Therapeutics AG stock price performed over time
Intraday
0%
1 week
4.55%
1 month
6.64%
1 year
-5.83%
YTD
2.96%
QTD
-1.01%

Financial performance

How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$13.39M
Gross profit
$13.39M
Operating income
-$534.34M
Net income
-$451.14M
Gross margin
100%
Net margin
-3,368.7%
The operating margin has dropped by 175% year-on-year but it has surged by 75% since the previous quarter
The net margin has dropped by 174% year-on-year but it has surged by 76% since the previous quarter
The company's gross profit has shrunk by 65% YoY
The revenue has dropped by 65% year-on-year

Price vs fundamentals

How does CRSP's price correlate with its fundamentals

Growth

What is CRISPR Therapeutics AG's growth rate over time

Valuation

What is CRISPR Therapeutics AG stock price valuation
CRSP P/E details
P/E
N/A
P/B
2.98
P/S
389.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
426.02
The EPS is up by 24% since the previous quarter and by 12% year-on-year
The price to book (P/B) is 24% higher than the 5-year quarterly average of 2.4 and 6% higher than the last 4 quarters average of 2.8
The equity has decreased by 3.7% QoQ but it has increased by 2.1% YoY
The revenue has dropped by 65% year-on-year
The price to sales (P/S) is 48% lower than the last 4 quarters average of 751.1 but 15% higher than the 5-year quarterly average of 339.0

Efficiency

How efficient is CRISPR Therapeutics AG business performance
The return on sales has dropped by 174% year-on-year but it has surged by 76% since the previous quarter
The ROIC rose by 29% QoQ and by 21% YoY
The company's return on assets rose by 25% QoQ and by 15% YoY
The ROE has grown by 21% from the previous quarter and by 3.2% YoY

Dividends

What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRSP.

Financial health

How did CRISPR Therapeutics AG financials performed over time
CRISPR Therapeutics AG's total assets is 193% more than its total liabilities
The total liabilities has surged by 184% year-on-year
CRISPR Therapeutics AG's total assets has increased by 31% YoY but it has decreased by 2.8% from the previous quarter
The debt is 55% smaller than the equity
CRSP's debt to equity is up by 4.7% QoQ
The equity has decreased by 3.7% QoQ but it has increased by 2.1% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.